Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study - PubMed
3 days ago
- #Pseudomonas aeruginosa
- #antibiotic resistance
- #clinical outcomes
- The study evaluated resistance to novel β-lactam/β-lactamase inhibitors (βL/βLIs) among carbapenem-resistant Pseudomonas aeruginosa (CRPA) isolates from 35 hospitals across nine countries.
- Susceptibility rates among 800 CRPA isolates were 69% for ceftolozane-tazobactam (C/T), 67% for ceftazidime-avibactam (CZA), and 33% for imipenem-relebactam (I/R).
- US isolates showed higher susceptibility compared to non-US isolates, and isolates with carbapenemases were significantly less susceptible than those without carbapenemases.
- Thirty-day mortality and desirability of outcome rankings (DOOR) were similar between patients infected with susceptible vs. non-susceptible isolates overall, but patients with bacteremia from C/T-non-susceptible isolates had a lower probability of better DOOR outcomes.
- The findings highlight the need for additional treatment options for CRPA infections, especially outside the US and in carbapenemase-producing strains.